Segundo Mariz

1.6k total citations
40 papers, 598 citations indexed

About

Segundo Mariz is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Segundo Mariz has authored 40 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Surgery. Recurrent topics in Segundo Mariz's work include Diabetes Treatment and Management (12 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Metabolism, Diabetes, and Cancer (7 papers). Segundo Mariz is often cited by papers focused on Diabetes Treatment and Management (12 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Metabolism, Diabetes, and Cancer (7 papers). Segundo Mariz collaborates with scholars based in Netherlands, Portugal and Germany. Segundo Mariz's co-authors include Ian W Campbell, Bernard Burtin, Bruno Sepodes, Torsten Zuberbier, B. M. Henz, U.‐F. Haustein, Violeta Stoyanova‐Beninska, John E. Ware, Patrick Marquis and B Valentin and has published in prestigious journals such as Nature Reviews Drug Discovery, Endocrinology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Segundo Mariz

38 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Segundo Mariz Netherlands 14 187 144 139 125 87 40 598
Nobuhiro Maruyama Japan 14 164 0.9× 273 1.9× 66 0.5× 115 0.9× 36 0.4× 26 684
Greg Ball United States 13 235 1.3× 35 0.2× 72 0.5× 13 0.1× 88 1.0× 34 861
Gary B. Friedman United States 8 226 1.2× 79 0.5× 17 0.1× 131 1.0× 32 0.4× 13 802
Ronan Calvez United Kingdom 11 450 2.4× 127 0.9× 21 0.2× 124 1.0× 43 0.5× 16 962
Mette Gyldenløve Denmark 13 126 0.7× 90 0.6× 63 0.5× 26 0.2× 56 0.6× 31 596
Ettore Cianchetti Italy 18 278 1.5× 69 0.5× 15 0.1× 19 0.2× 38 0.4× 41 941
Pilar Mur Spain 15 188 1.0× 32 0.2× 11 0.1× 49 0.4× 50 0.6× 37 648
Ban B. Dawood United Kingdom 13 164 0.9× 23 0.2× 53 0.4× 33 0.3× 36 0.4× 15 713
Walter Voigt United States 13 160 0.9× 64 0.4× 252 1.8× 13 0.1× 55 0.6× 34 825
Yuwen Su China 12 323 1.7× 82 0.6× 16 0.1× 11 0.1× 83 1.0× 25 900

Countries citing papers authored by Segundo Mariz

Since Specialization
Citations

This map shows the geographic impact of Segundo Mariz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Segundo Mariz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Segundo Mariz more than expected).

Fields of papers citing papers by Segundo Mariz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Segundo Mariz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Segundo Mariz. The network helps show where Segundo Mariz may publish in the future.

Co-authorship network of co-authors of Segundo Mariz

This figure shows the co-authorship network connecting the top 25 collaborators of Segundo Mariz. A scholar is included among the top collaborators of Segundo Mariz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Segundo Mariz. Segundo Mariz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Palomo, Gloria M., Enrico Costa, Darius Matusevičius, et al.. (2024). Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene Therapy. 31(7-8). 366–377. 5 indexed citations
2.
Palomo, Gloria M., Enrico Costa, Darius Matusevičius, et al.. (2023). The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products. Molecular Therapy. 31(12). 3414–3423. 7 indexed citations
3.
Mariz, Segundo, et al.. (2021). Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation. Frontiers in Oncology. 11. 809035–809035. 2 indexed citations
4.
Capovilla, Giuseppe, Laura Fregonese, Matthias P. Hofer, et al.. (2019). Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases. Drug Discovery Today. 25(2). 274–291. 4 indexed citations
5.
Stoyanova‐Beninska, Violeta, Giuseppe Capovilla, Matthias P. Hofer, et al.. (2017). Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions. Drug Discovery Today. 23(1). 26–48. 11 indexed citations
6.
Tsigkos, Stelios, Matthias P. Hofer, Segundo Mariz, et al.. (2017). Establishing rarity in the context of orphan medicinal product designation in the European Union. Drug Discovery Today. 23(3). 681–686. 7 indexed citations
7.
Mariz, Segundo, Violeta Stoyanova‐Beninska, Patrick Celis, et al.. (2017). Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Frontiers in Medicine. 4. 53–53. 24 indexed citations
8.
Ecker, Andrea, Segundo Mariz, Koen Norga, et al.. (2017). Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations. Archives of Disease in Childhood. 103(5). 427–430. 2 indexed citations
9.
Mariz, Segundo, et al.. (2016). Worldwide collaboration for orphan drug designation. Nature Reviews Drug Discovery. 15(6). 440–441. 28 indexed citations
10.
Tsigkos, Stelios, Segundo Mariz, Laura Fregonese, et al.. (2014). Use of biomarkers in the context of orphan medicines designation in the European Union. Orphanet Journal of Rare Diseases. 9(1). 13–13. 6 indexed citations
11.
Mariz, Segundo, et al.. (2012). The development and registration of topical pharmaceuticals. International Journal of Pharmaceutics. 435(1). 22–26. 18 indexed citations
12.
Roden, Michael, Segundo Mariz, Alessandra Rosalba Brazzale, & Giovanni Pacini. (2008). Free fatty acid kinetics during long‐term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. Journal of Internal Medicine. 265(4). 476–487. 15 indexed citations
13.
Tilden, Dominic, et al.. (2007). A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK. PharmacoEconomics. 25(1). 39–54. 26 indexed citations
14.
Comaschi, Marco, et al.. (2007). The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. Nutrition Metabolism and Cardiovascular Diseases. 18(5). 373–379. 13 indexed citations
15.
Perriello, G., Simone Pampanelli, Paolo Brunetti, Cinzia Di Pietro, & Segundo Mariz. (2007). Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. Diabetes and Vascular Disease Research. 4(3). 226–230. 7 indexed citations
16.
Charbonnel, B, Michael Roden, Richard Urquhart, et al.. (2005). Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia. 48(3). 553–560. 20 indexed citations
17.
Roden, Michael, Markku Laakso, Don Johns, et al.. (2005). Long‐term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabetic Medicine. 22(8). 1101–1106. 17 indexed citations
18.
Urquhart, Richard, et al.. (2004). Effects of pioglitazone on the components of diabetic dyslipidaemia: Results of double-blind, multicentre, randomised studies. International Journal of Clinical Practice. 58(10). 907–912. 14 indexed citations
19.
Bousquet, Jean, Jacques Duchateau, C. Fayol, et al.. (1996). Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. Journal of Allergy and Clinical Immunology. 98(2). 309–316. 92 indexed citations
20.
Zuberbier, Torsten, et al.. (1996). Double-Blind Crossover Study of High-Dose Cetirizine in Cholinergic Urticaria. Dermatology. 193(4). 324–327. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobuhiro Maruyama Breakdown of academic impact, for papers by Greg Ball Breakdown of academic impact, for papers by Gary B. Friedman Breakdown of academic impact, for papers by Ronan Calvez Breakdown of academic impact, for papers by Mette Gyldenløve Breakdown of academic impact, for papers by Ettore Cianchetti Breakdown of academic impact, for papers by Pilar Mur Breakdown of academic impact, for papers by Ban B. Dawood Breakdown of academic impact, for papers by Walter Voigt Breakdown of academic impact, for papers by Yuwen Su
Rankless by CCL
2026